Quarterly report pursuant to Section 13 or 15(d)

Subsequent event - Additional Information (Details)

v3.23.1
Subsequent event - Additional Information (Details) - USD ($)
Mar. 22, 2023
Mar. 19, 2023
Dec. 28, 2022
Oct. 01, 2022
Series S Convertible Preferred Stock        
Subsequent Event [Line Items]        
fair Value of the Shares     100,000  
fair market value     $ 14,500,000  
Asset Purchase Agreement        
Subsequent Event [Line Items]        
Common Stock, par value       $ 0.032
Subsequent Event | Series S Convertible Preferred Stock | Soin Therapeutics L L C Member        
Subsequent Event [Line Items]        
Business combination, description     Dr. Soin may convert up to three million dollars of value of the Series S Stock into shares of the Company's common stock commencing one year from the closing and may convert up to an additional $10 million of value of the Series S Stock into shares of the Company's common stock from and after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) 10 years from the closing. Further, during the 10-year period following the closing, Dr. Soin may convert up to an additional $17 million of value at a rate of five percent of the gross revenues that the Company receives in connection with sales or license revenue from the product.In connection with the merger, the Company employed an independent third-party firm to assess the fair value of the 100,000 shares of Series S Stock issued. The assessment determined that the fair market value of the Series S Stock was approximately $14.5 million, which was allocated to the intellectual property acquired.  
Subsequent Event | Sti Merger Sub Inc | Soin Therapeutics L L C Member        
Subsequent Event [Line Items]        
Common stock, shares outstanding, percentage     4.99%  
Subsequent Event | Sti Merger Sub Inc | Series S Convertible Preferred Stock | Soin Therapeutics L L C Member        
Subsequent Event [Line Items]        
Preferred stock, shares authorized (in shares)     200,000  
Preferred stock, par value     $ 300.00  
Stock issued during period, shares, acquisition     100,000  
Stock issued during period, value, acquisition     $ 13,000,000  
Stock issued during period, additional value, acquisitions     17,000,000  
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable     30,000,000  
Subsequent Event | Stock Conversion1 | Series S Convertible Preferred Stock | Soin Therapeutics L L C Member        
Subsequent Event [Line Items]        
Conversion of stock, amount converted     3,000,000  
Subsequent Event | Stock Conversion2 | Series S Convertible Preferred Stock | Soin Therapeutics L L C Member        
Subsequent Event [Line Items]        
Conversion of stock, amount converted     10,000,000  
Subsequent Event | Stock Conversion3 | Series S Convertible Preferred Stock | Soin Therapeutics L L C Member        
Subsequent Event [Line Items]        
Conversion of stock, amount converted     $ 17,000,000  
Subsequent Event | Stock Purchase Agreement | Subsidiaries        
Subsequent Event [Line Items]        
Reduction in liabilities   $ 17,600,000    
Advance payment   1,000,000    
Proceeds for equity   $ 1,000    
Stock purchase agreement description   Each monthly payment is to be the greater of (a) $140,000 (or $100,000 for each January and February during the 15-year payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows: (i) 5% of the Subsidiaries’ aggregate gross revenues up to $2,000,000 for the relevant month, plus (ii) 4% of the Subsidiaries’ aggregate gross revenues between $2,000,000 and $3,000,000 for the relevant month, plus (iii) 3% of the Subsidiaries aggregate gross revenues over $3,000,000 for the relevant month.    
Subsequent Event | Stock Purchase Agreement | Subsidiaries | Maximum        
Subsequent Event [Line Items]        
Proceeds from subsidiaries   $ 24,000,000.0    
Subsequent Event | Securities Purchase Agreement        
Subsequent Event [Line Items]        
Common stock offering shares 361,000      
Common Stock, par value $ 0.001      
Common stock purchase price per share $ 1.17      
Proceeds from sale of common stock $ 422,000